5 Kazia Theraputics Limited Annual Report 2023 Closure of an equity financing, with a total of A$7.106 million raised from a placement to professional and sophisticated investors and the associated Share Purchase Plan for eligible shareholders. Kazia enters into a collaboration with the Australian and New Zealand Children’s Haematology / Oncology Group (ANZCHOG) for the OPTIMISE phase II clinical study which will examine paxalisib in children with advanced solid tumours, including brain tumours. New data for both paxalisib and EVT801 presented at the Annual Meeting of the American Association for Cancer Research (AACR). Dr John Friend appointed Chief Executive Officer (CEO) following the resignation of Dr James Garner as CEO and Managing Director. Dr John Friend participates in the Cancer Moonshot Brain Cancers Forum on GBM and DIPG at the White House in Washington, DC, USA. Highly experienced corporate lawyer Ms Ebru Davidson appointed to the Board as Non-Executive Director, bringing strong governance insights on corporate legal strategy and risk management. Kazia announces its support of the University of Sydney on a molecularlyguided phase II clinical study, LUMOS2, to examine paxalisib in adult patients with recurrent/ progressive isocitrate dehydrogenase (IDH) mutant grade 2 and 3 gliomas (G2/3 gliomas). The study will be sponsored by the University of Sydney, and coordinated by NHMRC Clinical Trials Centre, University of Sydney, in collaboration with COGNO (CoOperative Trials Group for NeuroOncology). FEB 23 MAR 23 APR 23 MAY 23 JUN 23 JUN 23 Chairman and CEO’s Letter Key Milestones Introduction to Kazia’s CEO Pipeline Review Environment, Society and Governance Financial Reports
RkJQdWJsaXNoZXIy MjE2NDg3